Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Allergan to Acquire Vitae for $639M

By Meg Snyder | September 14, 2016

Allergan has entered into a definitive agreement to acquire Vitae Pharmaceuticals Inc. for $639 million, which was unanimously approved by the Boards of Directors of both companies.

Vitae, a development-stage biotechnology company, is based in Fort Washington Pennsylvania and does not currently have a product on the market.

This acquisition will add a number of dermatology products to Allergan’s dermatology product pipeline, including:

  • VTP-43742 (an orally active RORγt [retinoic acid receptor-related orphan receptor gamma] inhibitor): a potential treatment for psoriasis and other autoimmune disorders, which recently completed a Phase 2 trial
  • VTP-38543 (a topical LXRβ [Liver X Receptor beta] selective agonist): a potential treatment of atopic dermatitis, which is currently in a Phase 2a proof-of-concept clinical trial

“The acquisition of Vitae is a strategic investment for Allergan that adds strength and depth to our innovative medical dermatology franchise,” said Brent Saunders, CEO and President of Allergan.

“The Vitae team has been tremendously successful in discovering and conducting early development work in areas of medicine that can benefit from significant innovation,” said Jeff Hatfield, President and Chief Executive Officer of Vitae. “I believe our programs will be poised for successful development as part of Allergan’s portfolio.”

Allergan will acquire Vitae for $21 per share, which is more than double Vitae’s closing price of $8.10 on Tuesday (9/13).

Allergan is best known for its blockbuster wrinkle treatment, Botox, which is also approved to treat muscle spasms and bladder control.

For more information, view the press release. 

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE